| Name | Title | Contact Details |
|---|
Diabetes Health Net is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pascal Metrics is the preeminent provider in the healthcare industry of real-time patient safety and clinical improvement services to reduce patient harm and related cost.
Back in Motion is the British Columbia leader in rehabilitation, disability prevention and employment solutions. Since 1993, BiM has provided quality innovative solutions to workers, employers and job seekers, as well as to program funders. We have grown to over 200 employees and contractors, and presently deliver rehabilitation, assessment, and employment programs and services in Richmond, Surrey (Newton), Surrey (Panorama), Vancouver, Coquitlam, Port Coquitlam, and Langley. Back in Motion has received recognition as an excellent workplace (Great Place to Work Institute Canada 2006-2008, including being named the #1 workplace in Canada in 2007; Psychologically Healthy Workplace Award 2009; Richmond News Profile of Excellence 2013).
HealthCare Ventures LLC is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.